{"id":"NCT03329846","sponsor":"Bristol-Myers Squibb","briefTitle":"An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma","officialTitle":"A Phase 3, Randomized, Double-blind Study of BMS-986205 Combined With Nivolumab Versus Nivolumab in Participants With Metastatic or Unresectable Melanoma That is Previously Untreated","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-11-30","primaryCompletion":"2020-07-02","completion":"2020-07-02","firstPosted":"2017-11-06","resultsPosted":"2021-07-09","lastUpdate":"2021-07-09"},"enrollment":20,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Melanoma","Skin Cancer"],"interventions":[{"type":"DRUG","name":"BMS-986205","otherNames":[]},{"type":"BIOLOGICAL","name":"Nivolumab","otherNames":["BMS-936558"]},{"type":"DRUG","name":"Placebo","otherNames":["BMS-986205 matching placebo"]}],"arms":[{"label":"Nivolumab + Placebo","type":"ACTIVE_COMPARATOR"},{"label":"Nivolumab + BMS-986205","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to see if BMS-986205 combined with nivolumab, compared to nivolumab by itself, is more effective in treating Melanoma that has spread or is unable to be removed by surgery, and has not previously been treated","primaryOutcome":{"measure":"Number of Participants Experiencing Adverse Events","timeFrame":"From first dose to 30 days following last dose (up to approximately 25 months)","effectByArm":[{"arm":"Nivolumab + BMS-986205","deltaMin":0,"sd":null},{"arm":"Nivolumab","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":4},"locations":{"siteCount":63,"countries":["United States","Australia","Canada","Czechia","France","Germany","Greece","Ireland","Italy","Japan","Netherlands","New Zealand","Poland","Spain","Switzerland","United Kingdom"]},"refs":{"pmids":[],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","https://www.bmsstudyconnect.com/s/US/English/USenHome","https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html","https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":10},"commonTop":["Nausea","Asthenia","Decreased appetite","Arthralgia","Fatigue"]}}